Researchers from Promatix Biosciences Ltd. presented preclinical data on PBS29301A, a first-in-class bispecific ADC developed using Promatix’s proprietary proteomics-based discovery platform.

In a recent study published in Molecular Therapy: Oncology, researchers from the City of Hope National Medical Center and Beckman Research Institute (USA) and collaborators aimed to identify differentially expressed genetic pathways in glioblastoma multiforme (GBM) tumor cells after 48 hours of hypoxia treatment by performing RNA sequencing.

To overcome the challenges of current CAR T-cell strategies and enhance their efficacy and specificity for acute myeloid leukemia, researchers at the Sino-American Cancer Foundation and collaborating institutions have developed a nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1).

Breezebio Inc., formerly known as Genedit Inc., has closed $60 million in series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s Nanogalaxy delivery platform.

Kivu Bioscience Inc. has announced receipt of Human Research Ethics Committee approval and clinical trial notification clearance in Australia to initiate a first-in-human trial of KIVU-305, its CEACAM5-targeted antibody-drug conjugate.